Page 47 - 2020_07-Haematologica-web

CNS-MM
9. Paludo J, Painuly U, Kumar S, et al. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016;16(11):644-654.
10. Gangatharan SA, Carney DA, Prince HM, et al. Emergence of central nervous system myeloma in the era of novel agents. Hematol Oncol. 2012;30(4):170-174.
11. Fassas AB, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with unfavorable chro- mosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45(2):291-300.
12. Lee D, Kalff A, Low M, et al. Central nerv- ous system multiple myeloma--potential roles for intrathecal therapy and measure- ment of cerebrospinal fluid light chains. Br J Haematol. 2013;162(3):371-375.
13. Abdallah AO, Atrash S, Shahid Z, et al. Patterns of central nervous system involve- ment in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(3):211-214.
14. Gertz MA. Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013;54(4):681-682.
15. Chen CI, Masih-Khan E, Jiang H, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162(4):483-488.
16. Harrison SJ, Spencer A, Quach H. Myeloma of the central nervous system - an ongoing conundrum! Leuk Lymphoma. 2016;57(7): 1505-1506.
17. Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, et al. Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report. J Oncol Pharm Pract. 2019;25(4):998-1002.
18. Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280-284.
19. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transi- tion and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105(1):317-323.
20. Sheth N, Yeung J, Chang H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33(10):1357-1360.
21. Deng S, Xu Y, An G, et al. Features of extramedullary disease of multiple myelo- ma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15(5):286-291.
22. Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalido- mide on extramedullary myeloma. Leukemia. 2011;25(6):906-908.
23. Varga C, Xie W, Laubach J, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-borte- zomib combinations. Br J Haematol. 2015;169(6):843-850.
24. Chang WJ, Kim SJ, Kim K. Central nervous system multiple myeloma: a different cyto- genetic profile? Br J Haematol. 2014;164 (5):745-748.
25. Majd N, Wei X, Demopoulos A, Hormigo A,
Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leuk Lymphoma. 2016;57(7): 1709-1713.
26. Gozzetti A, Cerase A, Lotti F, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574-1584.
27. Dias A, Higashi F, Peres ALM, Cury P, Crusoe EQ, Hungria VTM. Multiple myeloma and central nervous system involvement: experience of a Brazilian cen- ter. Rev Bras Hematol Hemoter. 2018;40 (1):30-36.
28. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diag- nosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
40. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9(3):225-229.
41. Bommer M, Kull M, Teleanu V, et al. Leptomeningeal Myelomatosis: A Rare but Devastating Manifestation of Multiple Myeloma Diagnosed Using Cytology, Flow Cytometry, and Fluorescent in situ Hybridization. Acta Haematol. 2018;139 (4):247-254.
42. Ren H, Zou Y, Zhao Y, et al. Cerebrospinal Fluid Cytological Diagnosis in Multiple Myeloma With Leptomeningeal Involvement: A Report of Two Cases. Diagn Cytopathol. 2017;45(1):66-68.
43. Peter A. The plasma cells of the cere- brospinal fluid. J Neurol Sci. 1967;4(2):227-
29. Marchesi F, Masi S, Summa V, et al. Flow 239.
cytometry characterization in central nerv- ous system and pleural effusion multiple myeloma infiltration: an Italian national can- cer institute experience. Br J Haematol. 2016;172(6):980-982.
30. Greil C, Engelhardt M, Ihorst G, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term sur- vival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019;104(2):370-379.
31. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allo- geneic hematopoietic stem cell transplan- tation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 2004;34(12): 1057-1065.
32. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117(1):103-108.
33. Chang H, Bartlett ES, Patterson B, Chen CI, Yi QL. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol. 2005;129(4):539-541.
44. Fukunaga H, Mutoh T, Tatewaki Y, et al. Neuro-Myelomatosis of the Brachial Plexus - An Unusual Site of Disease Visualized by FDG-PET/CT: A Case Report. Am J Case Rep. 2017;18:478-481.
45. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43(11):1457-1463.
46. Mendez CE, Hwang BJ, Destian S, Mazumder A, Jagannath S, Vesole DH. Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10(3):220-223.
47. Anderson KC. Lenalidomide and thalido- mide: mechanisms of action--similarities and differences. Semin Hematol. 2005;42(4 Suppl 4):S3-8.
48. Nahi H, Svedmyr E, Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous sys- tem involvement. Eur J Haematol. 2014;92 (5):454-455.
49. Muscal JA, Sun Y, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol. 2012;69(4):943-947.
50. Hattori Y, Yabe M, Okamoto S, Morita K, Tanigawara Y, Ikeda Y. Thalidomide for the treatment of leptomeningeal multiple myeloma. Eur J Haematol. 2006;76(4):358-
34. Liu XJ, Wang FX, Yang L, et al. One Case of
Multiple Myeloma with Central Nervous
System Infiltration. Zhongguo Shi Yan Xue
Ye Xue Za Zhi. 2015;23(3):742-745. 359.
35. Marini A, Carulli G, Lari T, et al. Myelomatous meningitis evaluated by mul- tiparameter flow cytometry : report of a case and review of the literature. J Clin Exp Hematop. 2014;54(2):129-136.
36. Lopes AC, Xavier FD, de Souza Barroso R, Gomes HR, Sales MM. Massive central nervous system infiltration by CD56-posi- tive plasma cells in multiple myeloma. Cytopathology. 2017;28(2):172-174.
37. Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifi- cations for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):61-72.
38. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lym- phoma-like myeloma. Ann Intern Med. 1989;110(7):521-525.
39. Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116(2):273- 277.
51. Vicari P, Ribas C, Sampaio M, et al. Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? Eur J Haematol. 2003;70(3):198-199.
52. Katodritou E, Terpos E, Kastritis E, et al. Lack of survival improvement with novel anti- myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol. 2015;94(12):2033-2042.
53. Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenviron- ment in murine models. PLoS One. 2013;8(8):e71754.
54. Mussetti A, Dalto S, Montefusco V. Effective treatment of pomalidomide in central nerv- ous system myelomatosis. Leuk Lymphoma. 2013;54(4):864-866.
55. Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-mul- tiple myeloma. Br J Haematol. 2017;177(2): 221-225.
56. Villela L, Garcia M, Caballero R, Borbolla-
haematologica | 2020; 105(7)
1789